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Abstract
 
An unusual cytogenetic rearrangement, described as ins(22;9)(q11;q34q21), was detected in a 49-
year-old male patient diagnosed with chronic myeloid leukemia (CML). Reverse transcriptase
polymerase chain reaction (RT-PCR) revealed a b3a2 fusion transcript. In order to confirm the cy-
togenetic findings and fully characterize the inverted insertion, we performed fluorescence in situ
hybridization (FISH) assays using locus-specific and whole chromosome painting probes. Our
FISH analysis showed the presence of the 
 
BCR/ABL
 
 fusion gene, verified the insertion and deter-
mined that the breakpoint on chromosome 22 where the insertion took place was located proximal
to the 
 
BCR
 
 gene and distal to the 
 
TUPLE1
 
 gene on 22q11. © 2001 Elsevier Science Inc. All
 
rights reserved.
 
1. Introduction
 
Chronic myeloid leukemia (CML) is cytogenetically
characterized by the presence of the Philadelphia chromo-
some (Ph), which results from a reciprocal t(9;22)(q34;q11)
translocation and is found in about 90–95% of CML pa-
tients. The molecular consequence of the t(9;22) is the fu-
sion of the 3
 
9
 
 segment of the 
 
ABL
 
 gene from 9q34 to the 5
 
9
 
part of the 
 
BCR
 
 gene located at 22q11, giving rise to a chi-
meric 
 
BCR/ABL
 
 gene, which encodes a fusion protein with
prominent tyrosine kinase activity and transforming ability
[1]. Ph variants are found in 5% of CML patients. Such
variants consist of complex translocations among three or
more chromosomes including 9 and 22 and sometimes re-
sult in spuriously Ph negative but 
 
BCR/ABL
 
 positive CML
[2]. In these cases, fluorescence in situ hybridization (FISH)
is a useful technique to determine the location of the 
 
BCR/
ABL
 
 fusion gene [3]. Here, we present the characterization
by FISH of a complex inverted insertion of chromosome 9
into chromosome 22 in a case of CML.
 
2. Materials and methods
 
2.1. Case report
 
In January 1999, a 49-year-old man was referred to the
Department of Hematology of the Hospital Miguel Servet
(Zaragoza, Spain) for evaluation of fatigue, weight loss, and
abdominal discomfort. Physical examination revealed a pal-
pable abdominal mass in the left side, 12 cm below costal
limits. Neither the personal nor the familiar history showed
relevant data. Hematological parameters were as follows:
hemoglobin 104 g/L; hematocrit: 32%, platelets: 432 
 
3
 
 10
 
9
 
/
L; white blood cell (WBC) count: 630 
 
3
 
 10
 
9
 
/L. Peripheral
blood (MGG stain) with 25% neutrophils, 17% band, 13%
metamyelocytes, 32% myelocytes, 4% promyelocytes, 2%
blasts, 1% eosinophils, 4% basophils, and 2% lymphocytes.
Leukocyte alcaline phosphatase score was reduced to 4. All
laboratory values were normal with the exception of high
levels of lactate deshydrogenase (1151 UI/L, normal below
460 UI/L) and B
 
12
 
 vitamin levels (7329 pg/mL, normal
180–900 pg/mL). Bone marrow aspirate showed hypercel-
lularity with myeloid hyperplasia (94.2%), including 2.8%
myeloblasts, and 2.8% basophils. Decreased erythropoiesis
(2%) and increased number of hypolobulated and small size
megakaryocytes. Bone marrow biopsy showed marked hy-
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percellularity with loss of fat spaces and mild reticulin fi-
brosis of irregular distribution. Abdominal ultrasonography
confirmed splenomegaly. Cytogenetic analysis at diagnosis
revealed a t(9;22) variant, ins(22;9)(q11;q34q21), and the
presence of a b3a2 fusion transcript was detected by reverse
transcriptase polymerase chain reaction (RT-PCR). The pa-
tient was diagnosed as Philadelphia positive CML at stage 3
of Kantarjian. To additionally characterize this rare cytoge-
netic finding, we initiated FISH studies.
Cytoreduction was started with hydroxyurea 2 g qid po
until decreased WBC counts and spleen size were evident.
One month later the administration of alfa-Interferon [4], 3
mU qid sc was initiated with escalating doses until 9 mU
qid and cytosine arabinoside 10 mg/m
 
2
 
 10 days every 4
weeks. Six months later a partial hematological remission
was achieved with normal WBC counts, normal leukocyte
differential distribution, and spleen size reduced to 50% of
initial value. To date, 16 months after the diagnosis, the pa-
tient has remained stable in a chronic phase with partial he-
matological remission; a cytogenetic response has not ap-
peared yet.
 
2.2. Cytogenetic analysis, FISH and RT-PCR
 
Chromosomal analysis of tumor cells was performed on
bone marrow. Samples were processed using standard short-
term unstimulated cultures. Metaphases were G-banded ac-
cording to a conventional trypsin-Giemsa procedure.
FISH was performed according to manufacturer’s in-
structions using: whole painting probes for chromosomes 9
and 22 labeled with fluorescein (FITC) and cyanine 3
(Cy3), respectively (Cambio, Cambridge, UK), and two lo-
cus-specific probes to detect 
 
ABL
 
 (SpectrumOrange)/
 
BCR
 
(SpectrumGreen), and 
 
TUPLE1
 
 (SO)/ARSA (SG) genes
(Vysis, Downers Grove, IL, USA). Cytogenetic and FISH
data were described according to the International System
for Human Cytogenetic Nomenclature [5].
RT-PCR was performed according to routine protocols [6].
 
3. Results
 
A total of 50 metaphases were evaluated and in all of
them, the karyotype was described as: 46,XY,der(9)t(9;
22)(q13;q11),der(22)ins(22;9)(q11;q34q21). As it can be
observed in Fig. 1, the derivative chromosome 22 contains a
segment of chromosome 9 (4D), the fusion signal 
 
BCR5
 
9
 
-
ABL3
 
9
 
 appears near the telomere (4B) and both the 
 
ABL5
 
9
 
and 
 
TUPLE1
 
 signals are located close to the centromere (4B
and 4C). The derivative chromosome 9 contains part of
chromosome 22 (3D), one signal for the 
 
ARSA
 
 gene located
at 22q13 (3C) and no signals for 
 
ABL
 
 and 
 
BCR
 
 genes (not
shown). According to these findings, the derivative chro-
mosomes were described as: ish der(9)t(9;22)(q13;
q11)(wcp9
 
1
 
,wcp22
 
1
 
,ABL
 
2
 
,BCR
 
2
 
,ARSA
 
1
 
),der(22)
(22pter
 
fi
 
22q11.2::9q34
 
fi
 
9q21::22q11.2::9q34
 
fi
 
9qter)
(wcp22
 
1
 
,wcp9
 
1
 
,TUPLE1
 
1
 
,ABL
 
11
 
,BCR
 
1
 
). Fig. 1 shows
the ideograms of both normal and derivative chromosomes
9 and 22 and the chromosome pictures after G-banding,
painting FISH and locus-specific FISH with 
 
BCR/ABL
 
 and
DiGeorge probes. A b3a2 mRNA transcript was found by
RT-PCR indicating that the breakpoint was located within
the major breakpoint cluster region (M-bcr) of the 
 
BCR
 
 gene.
 
4. Discussion
 
Philadelphia chromosome cytogenetic variants in CML
are becoming easily characterized using FISH techniques
[2,7]. These t(9;22) variants usually involve a third chromo-
some and complex rearrangements involving only chromo-
somes 9 and 22 have been rarely described [8–10]. Like
classical t(9;22), these variants usually lead to a 
 
BCR/ABL
 
fusion, which can be confirmed by RT-PCR [11]. The clini-
cal course of these patients does not differ from that of pa-
tients carrying the classical t(9;22) [2]. Cytogenetic re-
sponses generally begin to appear from 3 to 12 months of
treatment with IFN-
 
a
 
 [12]. In our patient, although a partial
hematological remission was achieved, the cytogenetic re-
sponse had not appeared after 15 months of treatment with
IFN-
 
a
 
. We performed a complete genetic analysis of leuke-
mic cells from this CML patient and found a complex bal-
anced rearrangement between chromosomes 9 and 22 with-
out the Philadelphia chromosome, but with molecular
confirmation of the 
 
BCR/ABL
 
 fusion gene. G-banding kary-
otyping revealed a large derivative chromosome 22 and a
short derivative chromosome 9, which were described as:
46,XY,der(9)t(9;22)(q13;q11),der(22)ins(22;9)(q11;q34q21).
Fig. 1 shows both normal 9 and 22 chromosomes (I), the
different fragments after chromosome breakage (II), and
the complex alteration (III) as they were seen by the differ-
ent techniques. The 
 
ABL5
 
9
 
 (4B) signal is located near the
centromere on the der(22) thus confirming the inverted in-
sertion we had proposed initially. To locate the second
breakpoint on chromosome 22 we used the 
 
TUPLE1
 
 gene,
which is proximal to 
 
BCR
 
, and found that this gene was re-
tained on 22q11 (4C), hence the region where the 9q seg-
ment was inserted must be between those two genes. Ac-
cording to the genomic sequence of chromosome 22 (http://
www.sanger.ac.uk/HGP/Chr22/), our findings suggest that
the breakpoint must be approximately in a region between
3.2 Mb (TUPLE1) and 7.1 Mb (BCR) from the centromere.
Although we had cytogenetically described the der(22) as a
simple ins(22;9)(q11;q3421), after FISH, the description
of such chromosome became der(22)(22pter
 
fi
 
22q11.2::
9q34
 
fi
 
9q21::22q11.2::9q34
 
fi
 
9qter).
In order to explain the genesis of this variant t(9;22), we
propose two hypotheses: a two-step mechanism, in which a
classical t(9;22) took place followed by an inverted inser-
tion of an interstitial segment of the der(9) into the proximal
region of the Philadelphia chromosome; or a single-step
mechanism, in which all the fragments were split and rear-
ranged in a complex fashion at the same time. The first hy-
 J.I. Martín-Subero et al.  / Cancer Genetics and Cytogenetics 125 (2001) 167–170
 
169
Fi
g.
 1
. I
. I
de
og
ra
m
s o
f t
he
 n
or
m
al
 c
hr
om
os
om
es
 9
 an
d 
22
 sh
ow
in
g 
th
e p
os
iti
on
s o
f t
he
 d
iff
er
en
t p
ro
be
s w
e u
se
d 
w
ith
 th
ei
r r
es
pe
ct
iv
e 
co
lo
rs
. F
ig
ur
es
 1
A
 a
nd
 2
A
 sh
ow
 th
e 
G
-b
an
de
d 
ch
ro
m
os
om
es
,
1B
 a
nd
 2
B 
th
e c
hr
om
os
om
es
 af
te
r B
CR
/A
BL
 d
ua
l-c
ol
or
 F
IS
H
, 2
C 
th
e c
hr
om
os
om
e 2
2 
af
te
r u
sin
g 
th
e T
U
PL
E1
/A
RS
A
 F
IS
H
 p
ro
be
, a
nd
 1
D
 an
d 
2D
 th
e d
ua
l-c
ol
or
 p
ai
nt
in
g 
FI
SH
 fo
r c
hr
om
os
om
es
9 
an
d 
22
. I
I. 
Id
eo
gr
am
s d
isp
la
yi
ng
 th
e 
di
ffe
re
nt
 fr
ag
m
en
ts 
w
hi
ch
 w
er
e 
re
ar
ra
ng
ed
 to
 g
en
er
at
e 
th
e 
co
m
pl
ex
 a
be
rra
tio
n.
 II
I. 
Id
eo
gr
am
s 
o
f t
he
 d
er
(9)
 an
d d
er(
22
) s
ho
wi
ng
 th
e l
oc
ati
on
 of
 th
e p
rob
es
af
te
r F
IS
H
. F
ig
s. 
3A
 an
d 
4A
 re
pr
es
en
t G
-b
an
de
d 
ch
ro
m
os
om
es
, 4
B 
th
e d
er
(22
) a
fte
r B
CR
/A
BL
 du
al-
co
lor
 FI
SH
, 3
C 
an
d 4
C 
bo
th 
de
riv
ati
ve
 c
hr
om
os
om
es
 a
fte
r T
U
PL
E1
/A
RS
A
 F
IS
H
, a
nd
 3
D
 an
d
4D
 th
e 
du
al
-c
ol
or
 p
ai
nt
in
g 
FI
SH
 fo
r c
hr
om
os
om
es
 9
 an
d 
22
.
 170
 
J.I. Martín-Subero et al. / Cancer Genetics and Cytogenetics 125 (2001) 167–170
 
pothesis could not be confirmed because at diagnosis the
patient did not have a Ph chromosome; it is possible that the
clone with the insertion had a proliferative advantage over
the clone with the t(9;22), due perhaps to a second fusion
between genes involved in the insertion. Another possible
explanation that we can not rule out is that both the translo-
cation and the insertion took place as a two-step mechanism
in the same cell, leading to a single malignant clone.
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